Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19

Hanidziar, Dusan; Robson, Simon C.

doi:10.1152/ajplung.00304.2020

Cited by 46 publications

(43 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significantly, we found a persistent reduction in DLCO over the study period, consistent with earlier reports (E et al, 2021). Low DLCO could be caused by interstitial changes or pulmonary vascular abnormalities following COVID-19 infections (Lang et al, 2020;Patel et al, 2020;Hanidziar and Robson, 2021). Our study has shown that up to a third of COVID patients still have evidence of defect DLCO 1 year after discharge (Wu et al, 2021), although longer term follow-up with a larger cohort will be required to confirm this observation.…”

Section: Discussionmentioning

confidence: 56%

Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis

Guo

Jiang

Liu

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: To determine the respiratory outcomes in patients following COVID-19-related hospitalization.Methods: Systematic review and meta-analysis of the literature.Results: Forced vital capacity (FVC, % of predicted): 0–3 months post discharge: 96.1, 95% CI [82.1–110.0]; 3–6 months post discharge: 99.9, 95% CI [84.8, 115.0]; >6 months post discharge: 97.4, 95% CI [76.8–118.0]. Diffusing capacity of the lungs for carbon monoxide (DLCO, % of predicted): 0–3 months post discharge: 83.9, 95% CI [68.9–98.9]; 3–6 months post discharge: 91.2, 95% CI [74.8–107.7]; >6 months post discharge: 97.3, 95% CI [76.7–117.9]. Percentage of patients with FVC less than 80% of predicted: 0–3 months post discharge: 10%, 95% CI [6–14%]; 3–6 months post discharge: 10%, 95% CI [2–18%]; >6 months post discharge: 13%, 95% CI [8–18%]. Percentage of patients with DLCO less than 80% of predicted: 0–3 months post discharge: 48%, 95% CI [41–56%]; 3–6 months post discharge: 33%, 95% CI [23–44%]; >6 months post discharge: 43%, 95% CI [22–65%].Conclusion: The meta-analysis confirms a high prevalence of persistent lung diffusion impairment in patients following COVID-19-related hospitalization. Routine respiratory follow-up is thus strongly recommended.

show abstract

Section: Discussionmentioning

confidence: 56%

Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis

Guo

Jiang

Liu

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Lung diffusion impairment could be attributable to lung epithelial damage, or interstitial or pulmonary vascular abnormalities. [30][31][32] Lung structural abnormality during late recovery of SARS was associated with the lung diffusion impairment; 33 however, the association during convalescence after COVID-19 was unclear. We undertook an initial exploratory analysis on the basis of a small group of patients and found that lung imaging patterns at 12 months might be associated with lung diffusion impairment, which should be confirmed in a larger sample study.…”

Section: Discussionmentioning

confidence: 99%

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

et al. 2021

View full text Add to dashboard Cite

Background The full range of long-term health consequences of COVID-19 in patients who are discharged from hospital is largely unclear. The aim of our study was to comprehensively compare consequences between 6 months and 12 months after symptom onset among hospital survivors with COVID-19. MethodsWe undertook an ambidirectional cohort study of COVID-19 survivors who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7 and May 29, 2020. At 6-month and 12-month follow-up visit, survivors were interviewed with questionnaires on symptoms and health-related quality of life (HRQoL), and received a physical examination, a 6-min walking test, and laboratory tests. They were required to report their health-care use after discharge and work status at the 12-month visit. Survivors who had completed pulmonary function tests or had lung radiographic abnormality at 6 months were given the corresponding tests at 12 months. Non-COVID-19 participants (controls) matched for age, sex, and comorbidities were interviewed and completed questionnaires to assess prevalent symptoms and HRQoL. The primary outcomes were symptoms, modified British Medical Research Council (mMRC) score, HRQoL, and distance walked in 6 min (6MWD). Multivariable adjusted logistic regression models were used to evaluate the risk factors of 12-month outcomes. Findings 1276 COVID-19 survivors completed both visits. The median age of patients was 59•0 years (IQR 49•0-67•0) and 681 (53%) were men. The median follow-up time was 185•0 days (IQR 175•0-198•0) for the 6-month visit and 349•0 days (337•0-361•0) for the 12-month visit after symptom onset. The proportion of patients with at least one sequelae symptom decreased from 68% (831/1227) at 6 months to 49% (620/1272) at 12 months (p<0•0001). The proportion of patients with dyspnoea, characterised by mMRC score of 1 or more, slightly increased from 26% (313/1185) at 6-month visit to 30% (380/1271) at 12-month visit (p=0•014). Additionally, more patients had anxiety or depression at 12-month visit (26% [331/1271] at 12-month visit vs 23% [274/1187] at 6-month visit; p=0•015). No significant difference on 6MWD was observed between 6 months and 12 months. 88% (422/479) of patients who were employed before COVID-19 had returned to their original work at 12 months. Compared with men, women had an odds ratio of 1•43 (95% CI 1•04-1•96) for fatigue or muscle weakness, 2•00 (1•48-2•69) for anxiety or depression, and 2•97 (1•50-5•88) for diffusion impairment. Matched COVID-19 survivors at 12 months had more problems with mobility, pain or discomfort, and anxiety or depression, and had more prevalent symptoms than did controls.Interpretation Most COVID-19 survivors had a good physical and functional recovery during 1-year follow-up, and had returned to their original work and life. The health status in our cohort of COVID-19 survivors at 12 months was still lower than that in the control population.

show abstract

“…Among the main respiratory functional changes, alteration in gas transfer measured by diffusing capacity for carbon monoxide (D LCO ) has been documented up to 12 weeks of follow-up [13,[86][87][88]. D LCO alteration could be associated with interstitial and vascular damage, secondary to acute infection [89,90]. These features may depend on the severity of the disease during the acute COVID-19 [91][92][93].…”

Section: Discussionmentioning

confidence: 99%

Post-COVID Syndrome. A Case Series and Comprehensive Review

Anaya

Rojas

Salinas

et al. 2021

Preprint

View full text Add to dashboard Cite

The existence of a variety of symptoms with a duration beyond the acute phase of COVID-19, is referred to as post-COVID syndrome (PCS). We aimed to report a series of patients with PCS attending a Post-COVID Unit and offer a comprehensive review on the topic. Adult patients with previously confirmed SARS-CoV-2 infection were systematically assessed through a semi-structured and validated survey. Total IgG, IgA and IgM serum antibodies to SARS-CoV-2 were evaluated by an electrochemiluminescence immunoassay. A systematic review of the literature and meta‐analysis were conducted, following PRISMA guidelines. Univariate and multivariate methods were used to analyze data. Out of a total of 100 consecutive patients, 53 were women, the median of age was 49 years (IQR: 37.8 to 55.3), the median of post-COVID time after the first symptoms was 219 days (IQR: 143 to 258), and 65 patients were hospitalized during acute COVID-19. Musculoskeletal, digestive (i.e., diarrhea) and neurological symptoms including depression (by Zung scale) were the most frequent observed in PCS patients. A previous hospitalization was not associated with PCS manifestation. Arthralgia and diarrhea persisted in more than 40% of PCS patients. The median of anti-SARS-CoV-2 antibodies was 866.2 U/mL (IQR: 238.2 to 1681). Despite this variability, 98 patients were seropositive. Based on autonomic symptoms (by COMPASS 31) two clusters were obtained with different clinical characteristics. Levels of anti-SARS-CoV-2 antibodies were not different between clusters. A total of 40 articles (11,196 patients) were included in the meta‐analysis. Fatigue/muscle weakness, dyspnea, pain and discomfort, anxiety/depression and impaired concentration were presented in more than 20% of patients reported. In conclusion, PCS is mainly characterized by musculoskeletal, pulmonary, digestive and neurological involvement including depression. PCS is independent of severity of acute illness and humoral response. Long-term antibody responses to SARS-CoV-2 infection and a high inter-individual variability were confirmed. Future studies should evaluate the mechanisms by which SARS-CoV-2 may cause PCS and the best therapeutic options.

show abstract

Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19

Cited by 46 publications

References 47 publications

Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis

Respiratory Outcomes in Patients Following COVID-19-Related Hospitalization: A Meta-Analysis

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Post-COVID Syndrome. A Case Series and Comprehensive Review

Contact Info

Product

Resources

About